Transcription profiling of BRCA1;p53-deficient mouse mammary tumors with acquired docetaxel resistance to predict chemotherapy response

Using gene expression profiling of mammary tumors generated in a mouse model for BRCA1-associated breast cancer we have searched for markers that correlate with response to the anti-cancer drugs docetaxel or cisplatin. To validate the results, the analysis was done on 2 different platforms (39K Mouse Exonic Evidence Based Oligonucleotide (MEEBO), and 45K Illumina Sentrix mouse V6 single-channel bead arrays). Moreover, we analyzed mouse mammary tumors that had acquired docetaxel resistance on the MEEBO platform.